Valneva Shares at €2.70: Oversold RSI After a 38% Drop in Three Months
The stock of the Nantes-based vaccine specialist rose by 2.5% this Tuesday compared to the previous day, yet it does not offset a quarter of significant losses. Valneva is trading at €2.70, reflecting a nearly 38% decline over three months, in a Parisian market trending upwards with the CAC 40 up by 0.79% during the session.
Valneva's stock price stands at €2.70 in mid-afternoon, up 2.5% from the previous day's close of €2.64. This slight increase remains marginal compared to recent trends: the stock has lost 37.61% over three months and 2.52% over a year. The technical support identified at €2.58 held during recent sessions, partly explaining today's modest rebound. The RSI, a momentum indicator, is at 29, marking the threshold of the generally established oversold zone at 30. This level indicates that selling pressure has been particularly intense in recent weeks. Furthermore, the current price is significantly below the 50-day moving average (€4.00) and the 200-day average (€3.88), confirming a medium-term downward trend. At €2.70, the stock is in the lower part of the Bollinger Bands, at 33% of the range between the lower bound (€1.52) and the upper bound (€5.09).
Upcoming Financial Events and Sector Performance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Investors will gain a first glimpse of visibility on May 7, when Valneva is set to publish its first-quarter 2026 results. This event will be followed by the annual general meeting scheduled for June 1. These milestones could help clarify the operational and financial trajectory of the group, in a context where the stock has lost more than a third of its value in three months. On a European sector level, the session is mixed: Sanofi is up by 1.17% while UCB is down by 0.18%. Valneva's negative beta (-0.21) indicates an inverse correlation with the market, giving the stock an atypical profile within the Paris stock exchange. The half-year results, expected on August 13, will be another crucial milestone to assess the group's ability to stabilize its valuation.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.